Evidence map›Paper›PMID 28601576›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.

Qinggong Tang, Tadanobu Nagaya, Yi Liu, Jonathan Lin, Kazuhide Sato, Hisataka Kobayashi, Yu Chen

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Near-Infrared Photoimmunotherapy of Cancer.Accounts of chemical research · 2019
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qinggong TangUniversity of Maryland, Fischell Department of Bioengineering, 2218 Jeong H.Kim Engineering Building, College Park, MD 20742, United States.
Tadanobu NagayaNational Institute of Health, National Cancer Institute, Molecular Imaging Program, Bldg 10, Room B3B69, Bethesda, MD 20892-1088, United States.
Yi LiuUniversity of Maryland, Fischell Department of Bioengineering, 2218 Jeong H.Kim Engineering Building, College Park, MD 20742, United States.
Jonathan LinUniversity of Maryland, Fischell Department of Bioengineering, 2218 Jeong H.Kim Engineering Building, College Park, MD 20742, United States.
Kazuhide SatoNational Institute of Health, National Cancer Institute, Molecular Imaging Program, Bldg 10, Room B3B69, Bethesda, MD 20892-1088, United States.
Hisataka KobayashiNational Institute of Health, National Cancer Institute, Molecular Imaging Program, Bldg 10, Room B3B69, Bethesda, MD 20892-1088, United States. Electronic address: kobayash@mail.nih.gov.
Yu ChenUniversity of Maryland, Fischell Department of Bioengineering, 2218 Jeong H.Kim Engineering Building, College Park, MD 20742, United States. Electronic address: yuchen@umd.edu.

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Monitoring Photo-immunotherapy using Multi-channel Multi-modal Imaging NeedlesR03CA176027 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI CHEN, YU · 2014 to 2015
$152k
NCI NIH HHS R03 CA176027NCI NIH HHS ZIA BC011513
6 · The paper itself

Abstract

Photoimmunotherapy (PIT) is an emerging low side effect cancer therapy based on a monoclonal antibody (mAb) conjugated with a near-infrared (NIR) phthalocyanine dye IRDye 700DX. IR700 is fluorescent, can be used as an imaging agent, and also is phototoxic. It induces rapid cell death after exposure to NIR light. PIT induces highly selective cancer cell death, while leaving most of tumor blood vessels unharmed, leading to an effect called super-enhanced permeability and retention (SUPR). SUPR significantly improves the effectiveness of the anticancer drug. Currently, the therapeutic effects of PIT are monitored using the IR700 fluorescent signal based on macroscopic fluorescence reflectance imagery. This technique, however, lacks the resolution and depth information to reveal the intratumor heterogeneity of mAb-IR700 distribution. We applied a minimally invasive two-channel fluorescence fiber imaging system by combining the traditional fluorescence imaging microscope with two imaging fiber bundles (~0.85mm). This method monitored mAb-IR700 distribution and therapeutic effects during PIT at different intratumor locations (e.g., tumor surface vs. deep tumor) in situ and in real time simultaneously. This enabled evaluation of the therapeutic effects in vivo and treatment regimens. The average IR700 fluorescence intensity recovery after PIT to the tumor surface is 91.50%, while it is 100.63% in deep tumors. To verify the results, two-photon microscopy combined with a microprism was also used to record the mAb-IR700 distribution and fluorescence intensity of green fluorescent protein (GFP) at different tumor depths during PIT. After PIT treatment, there was significantly higher IR700 fluorescence recovery in deep tumor than in the tumor surface. This phenomenon can be explained by increased vascular permeability immediately after NIR-PIT. Fluorescence intensity of GFP at the tumor surface decreased significantly more compared to that of deep tumor and in controls (no PIT).

Indexed as

ImmunotherapyPhototherapyAnimalsAntibodies, MonoclonalCarbocyaninesCell Line, TumorFemaleFluorescent DyesGreen Fluorescent ProteinsImmunoglobulin GInfrared RaysMice, NudeNeoplasmsOrganophosphorus CompoundsPanitumumabTumor BurdenAntibodies, MonoclonalCarbocyaninesFluorescent DyesGreen Fluorescent ProteinsImmunoglobulin GIRD 700Organophosphorus CompoundsPanitumumabIntra-tumor heterogeneityPhotoimmunotherapy (PIT)Super-enhanced permeability and retention effectTwo-channel fluorescence imaging fiber bundleTwo-photon microscopy (TPM)

Identifiers

PMID28601576
PMCPMC5726775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.